<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01640340</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-10118</org_study_id>
    <secondary_id>NCI-2012-01009</secondary_id>
    <nct_id>NCT01640340</nct_id>
  </id_info>
  <brief_title>Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)</brief_title>
  <official_title>Pilot Study on the Efficacy of an Ondansetron Versus Palonosetron-containing Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Palonosetron is different from ondansetron because it stays in the body longer and may
      prevent nausea and vomiting for a longer period of time than ondansetron. It is standard
      practice to use dexamethasone and aprepitant with either ondansetron or palonosetron to
      prevent nausea and vomiting caused by highly emetogenic chemotherapy. Although these
      combinations are commonly used, they have never been compared to each other. The purpose of
      this study is to record the amount of nausea and vomiting, and the amount of &quot;rescue&quot;
      medication that is used with these two different anti-emetic regimens
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. The goal of this study is to evaluate the overall complete response rate (CR, no emesis
      and no use of rescue medication from 0 to 120 hours after chemotherapy) of two different
      antiemetic regimens (palonosetron + aprepitant + dexamethasone and ondansetron + aprepitant +
      dexamethasone) for patients undergoing the first cycle of highly emetogenic chemotherapy
      (HEC).

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive palonosetron hydrochloride intravenously (IV) 30 minutes prior to
      chemotherapy on day 1, aprepitant orally (PO) 60 minutes prior to chemotherapy on days 1-3,
      and dexamethasone PO 30 minutes prior to chemotherapy on days 1-4.

      ARM II: Patients receive ondansetron PO 30 minutes prior to chemotherapy on day 1 and
      aprepitant and dexamethasone as in Arm I.

      After completion of study treatment, patients are followed up for 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall CR(Complete Response)After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication</measure>
    <time_frame>Up to 120 hours after completion of chemotherapy</time_frame>
    <description>We will use exact binomial methods to estimate proportions and their associated 95% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute CR (Complete Response)</measure>
    <time_frame>0-24 hours after chemotherapy</time_frame>
    <description>After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication from time 0 to 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed CR (Complete Response)</measure>
    <time_frame>24-120 hours after chemotherapy</time_frame>
    <description>After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication From Time 24to 120 Hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Experienced Grade 1, 2 or 3 Nausea From Time 0 to 120 Hours</measure>
    <time_frame>Time 0 to 120 hours</time_frame>
    <description>The percentage of patients who experienced grade 1, 2 or 3 nausea from time 0 to 120 hours. Nausea graded using the National Cancer Institute (NCI) CTCAE (Common Toxicity Criteria for Adverse Effects)version 4.0 Nausea Grading Scale. Grade 1=Loss of appetite without alteration in eating habits, Grade 2= Oral intake decreased without significant weight loss, dehydration or malnutrition, Grade 3= Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Scores</measure>
    <time_frame>Up to 7 days after completion of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medication for Each Treatment Arm</measure>
    <time_frame>From time 0 to 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Experienced Grade 1, 2 or 3 Vomiting From Time 0 to 120 Hours</measure>
    <time_frame>From time 0 to 120 hours</time_frame>
    <description>The percentage of patients who experienced grade 1, 2 or 3 vomiting from time 0 to 120 hours. Nausea graded using the National Cancer Institute (NCI) CTCAE v 4.0 vomiting Grading Scale. Grade 1=Loss of appetite without alteration in eating habits, Grade 2= Oral intake decreased without significant weight loss, dehydration or malnutrition, Grade 3= Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (palonosetron hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive palonosetron hydrochloride IV 30 minutes prior to chemotherapy on day 1, aprepitant PO (by mouth) 60 minutes prior to chemotherapy on days 1-3, and dexamethasone PO 30 minutes prior to chemotherapy on days 1-4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (ondansetron)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ondansetron PO 30 minutes prior to chemotherapy on day 1 and aprepitant and dexamethasone as in Arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aprepitant</intervention_name>
    <description>Given by mouth</description>
    <arm_group_label>Arm I (palonosetron hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (ondansetron)</arm_group_label>
    <other_name>Emend</other_name>
    <other_name>L-754030</other_name>
    <other_name>MK-0869</other_name>
    <other_name>ONO-7436</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palonosetron hydrochloride</intervention_name>
    <description>Given IV(intervenous infusion)</description>
    <arm_group_label>Arm I (palonosetron hydrochloride)</arm_group_label>
    <other_name>Aloxi</other_name>
    <other_name>RS 25259-197</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (ondansetron)</arm_group_label>
    <other_name>GR 38032F</other_name>
    <other_name>GR-C507/75</other_name>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (palonosetron hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (ondansetron)</arm_group_label>
    <other_name>Aeroseb-Dex</other_name>
    <other_name>Decaderm</other_name>
    <other_name>Decadron</other_name>
    <other_name>DM</other_name>
    <other_name>DXM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed malignancy

          -  Chemotherapy naive or treated with only low or minimally emetogenic chemotherapy in
             the past (as defined by the National Comprehensive Cancer Network version [v].2.201
             Antiemetic Guidelines)

          -  Scheduled to receive the first dose of their first cycle of HEC

          -  Patients receiving multi-day chemotherapy, the HEC portion must be on day 1 and the
             remaining days of chemotherapy must be minimally emetogenic (i.e. fluorouracil)

          -  Performance status of Eastern Cooperative Oncology Group (ECOG) grade 0-2

          -  Able to provide informed consent

          -  Able to read and write in English or have someone that can that can translate to them
             and record their diary entries

          -  Able to take oral medications

          -  Patients are allowed to participate in a concurrent clinical trial, if the other
             trial:

               -  Does not mandate an antiemetic regimen that interferes with this study

               -  Allows antiemetic administration at the physician's discretion

               -  Does not prohibit the patient from participating in this study

          -  Patients must be willing to participate with daily diary entries for 5 days following
             chemotherapy, and agree to have a 5 minute follow-up call on day 2 or 3 and day 5, 6
             or 7

        Exclusion Criteria:

          -  Has stage IV (metastatic) disease

          -  Known hypersensitivity to ondansetron, palonosetron, aprepitant, or dexamethasone

          -  Have received or will receive agents that are strong cytochrome P450 3A4 (CYP450 3A4)
             inducers and/or inhibitors and known to cause clinically relevant drug interactions
             within one week prior to study treatment and continuing through day 5; any vomiting or
             retching within 24 hours before administration of chemotherapy

          -  Grade 2 nausea or greater, according to the Common Terminology Criteria for Adverse
             Events version 4.0 (CTCAE v 4.0) within 24 hours before administration of chemotherapy

          -  Received an antiemetic within 24 hours before study drug administration, excluding the
             use of benzodiazepines

          -  Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &gt; 2.5 times
             upper limit of normal

          -  Total bilirubin &gt; 1.5 times upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Layman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2012</study_first_submitted>
  <study_first_submitted_qc>July 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2012</study_first_posted>
  <results_first_submitted>July 19, 2013</results_first_submitted>
  <results_first_submitted_qc>July 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 7, 2013</results_first_posted>
  <last_update_submitted>October 13, 2013</last_update_submitted>
  <last_update_submitted_qc>October 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Rachel Layman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ondansetron</keyword>
  <keyword>palonosetron</keyword>
  <keyword>emetogenic chemotherapy</keyword>
  <keyword>HEC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
    <mesh_term>Emetics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were screened for eligibility during routine clinic visits by a physician, nurse practitioner or pharmacist involved in their care.</recruitment_details>
      <pre_assignment_details>Patients were stratified based upon their chemotherapy regimen (cisplatin versus noncisplatin containing) and then randomized to the ondansetron or palonosetron group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A (Palonosetron 0.25 mg IV on Day 1)</title>
          <description>Palonosetron 0.25 mg day 1; aprepitant 125 mg day 1, 80 mg days 2-3; dexamethasone 12 mg day 1, 8 mg day 2-4</description>
        </group>
        <group group_id="P2">
          <title>Arm B (Ondansetron 24 mg Oral on Day 1)</title>
          <description>Ondansetron 24 mg day 1; aprepitant 125 mg day 1, 80 mg day 2-3; dexamethasone 12 mg day 1, 8 mg day 2-4</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Overall Complete Response Rate</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A</title>
          <description>Palonosetron 0.25 mg day 1; aprepitant 125 mg day 1, 80 mg day 2-3; dexamethasone 12 mg day 1, 8 mg day 2-4</description>
        </group>
        <group group_id="B2">
          <title>Arm B</title>
          <description>Ondansetron 24 mg day 1; aprepitant 125 mg day 1, 80 mg day 2-3; dexamethasone 12 mg day 1, 8 mg day 2-4</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall CR(Complete Response)After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication</title>
        <description>We will use exact binomial methods to estimate proportions and their associated 95% confidence intervals.</description>
        <time_frame>Up to 120 hours after completion of chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Palonosetron 0.25 mg IV on Day 1)</title>
            <description>Palonosetron 0.25 mg IV once on day 1, 30 minutes prior to chemotherapy, aprepitant 125 mg orally once on day 1, 60 minutes prior to chemotherapy, then 80 mg once daily on days 2 and 3 at the same time, and dexamethasone 12 mg orally once on day 1, 30 minutes prior to chemotherapy, then 8 mg once daily on days 2 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Ondansetron 24 mg Oral on Day 1)</title>
            <description>Ondansetron 24 mg once orally on day 1, 30 minutes prior to chemotherapy, aprepitant 125 mg orally once on day 1, 60 minutes prior to chemotherapy, then 80 mg once daily on days 2 and 3, and dexamethasone 12 mg orally once on day 1, 30 minutes prior to chemotherapy, then 8 mg once daily on days 2 through 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall CR(Complete Response)After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication</title>
          <description>We will use exact binomial methods to estimate proportions and their associated 95% confidence intervals.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="40.8" upper_limit="84.6"/>
                    <measurement group_id="O2" value="40" lower_limit="19.1" upper_limit="63.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute CR (Complete Response)</title>
        <description>After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication from time 0 to 24 hours.</description>
        <time_frame>0-24 hours after chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Palonosetron 0.25 mg IV on Day 1)</title>
            <description>Palonosetron 0.25 mg IV once on day 1, 30 minutes prior to chemotherapy, aprepitant 125 mg orally once on day 1, 60 minutes prior to chemotherapy, then 80 mg once daily on days 2 and 3 at the same time, and dexamethasone 12 mg orally once on day 1, 30 minutes prior to chemotherapy, then 8 mg once daily on days 2 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Ondansetron 24 mg Oral on Day 1)</title>
            <description>Ondansetron 24 mg once orally on day 1, 30 minutes prior to chemotherapy, aprepitant 125 mg orally once on day 1, 60 minutes prior to chemotherapy, then 80 mg once daily on days 2 and 3, and dexamethasone 12 mg orally once on day 1, 30 minutes prior to chemotherapy, then 8 mg once daily on days 2 through 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute CR (Complete Response)</title>
          <description>After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication from time 0 to 24 hours.</description>
          <units>percentage of particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delayed CR (Complete Response)</title>
        <description>After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication From Time 24to 120 Hours.</description>
        <time_frame>24-120 hours after chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Palonosetron 0.25 mg IV on Day 1)</title>
            <description>Palonosetron 0.25 mg IV once on day 1, 30 minutes prior to chemotherapy, aprepitant 125 mg orally once on day 1, 60 minutes prior to chemotherapy, then 80 mg once daily on days 2 and 3 at the same time, and dexamethasone 12 mg orally once on day 1, 30 minutes prior to chemotherapy, then 8 mg once daily on days 2 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Ondansetron 24 mg Oral on Day 1)</title>
            <description>Ondansetron 24 mg once orally on day 1, 30 minutes prior to chemotherapy, aprepitant 125 mg orally once on day 1, 60 minutes prior to chemotherapy, then 80 mg once daily on days 2 and 3, and dexamethasone 12 mg orally once on day 1, 30 minutes prior to chemotherapy, then 8 mg once daily on days 2 through 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Delayed CR (Complete Response)</title>
          <description>After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication From Time 24to 120 Hours.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Experienced Grade 1, 2 or 3 Nausea From Time 0 to 120 Hours</title>
        <description>The percentage of patients who experienced grade 1, 2 or 3 nausea from time 0 to 120 hours. Nausea graded using the National Cancer Institute (NCI) CTCAE (Common Toxicity Criteria for Adverse Effects)version 4.0 Nausea Grading Scale. Grade 1=Loss of appetite without alteration in eating habits, Grade 2= Oral intake decreased without significant weight loss, dehydration or malnutrition, Grade 3= Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated.</description>
        <time_frame>Time 0 to 120 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Palonosetron 0.25 mg IV on Day 1)</title>
            <description>Palonosetron 0.25 mg IV once on day 1, 30 minutes prior to chemotherapy, aprepitant 125 mg orally once on day 1, 60 minutes prior to chemotherapy, then 80 mg once daily on days 2 and 3 at the same time, and dexamethasone 12 mg orally once on day 1, 30 minutes prior to chemotherapy, then 8 mg once daily on days 2 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Ondansetron 24 mg Oral on Day 1)</title>
            <description>Ondansetron 24 mg once orally on day 1, 30 minutes prior to chemotherapy, aprepitant 125 mg orally once on day 1, 60 minutes prior to chemotherapy, then 80 mg once daily on days 2 and 3, and dexamethasone 12 mg orally once on day 1, 30 minutes prior to chemotherapy, then 8 mg once daily on days 2 through 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Experienced Grade 1, 2 or 3 Nausea From Time 0 to 120 Hours</title>
          <description>The percentage of patients who experienced grade 1, 2 or 3 nausea from time 0 to 120 hours. Nausea graded using the National Cancer Institute (NCI) CTCAE (Common Toxicity Criteria for Adverse Effects)version 4.0 Nausea Grading Scale. Grade 1=Loss of appetite without alteration in eating habits, Grade 2= Oral intake decreased without significant weight loss, dehydration or malnutrition, Grade 3= Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale (VAS) Scores</title>
        <time_frame>Up to 7 days after completion of study treatment</time_frame>
        <population>VAS Scores were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Palonosetron 0.25 mg IV on Day 1)</title>
            <description>Palonosetron 0.25 mg IV once on day 1, 30 minutes prior to chemotherapy, aprepitant 125 mg orally once on day 1, 60 minutes prior to chemotherapy, then 80 mg once daily on days 2 and 3 at the same time, and dexamethasone 12 mg orally once on day 1, 30 minutes prior to chemotherapy, then 8 mg once daily on days 2 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Ondansetron 24 mg Oral on Day 1)</title>
            <description>Ondansetron 24 mg once orally on day 1, 30 minutes prior to chemotherapy, aprepitant 125 mg orally once on day 1, 60 minutes prior to chemotherapy, then 80 mg once daily on days 2 and 3, and dexamethasone 12 mg orally once on day 1, 30 minutes prior to chemotherapy, then 8 mg once daily on days 2 through 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS) Scores</title>
          <population>VAS Scores were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue Medication for Each Treatment Arm</title>
        <time_frame>From time 0 to 120 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Palonosetron 0.25 mg IV on Day 1)</title>
            <description>Palonosetron 0.25 mg IV once on day 1, 30 minutes prior to chemotherapy, aprepitant 125 mg orally once on day 1, 60 minutes prior to chemotherapy, then 80 mg once daily on days 2 and 3 at the same time, and dexamethasone 12 mg orally once on day 1, 30 minutes prior to chemotherapy, then 8 mg once daily on days 2 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Ondansetron 24 mg Oral on Day 1)</title>
            <description>Ondansetron 24 mg once orally on day 1, 30 minutes prior to chemotherapy, aprepitant 125 mg orally once on day 1, 60 minutes prior to chemotherapy, then 80 mg once daily on days 2 and 3, and dexamethasone 12 mg orally once on day 1, 30 minutes prior to chemotherapy, then 8 mg once daily on days 2 through 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Rescue Medication for Each Treatment Arm</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Experienced Grade 1, 2 or 3 Vomiting From Time 0 to 120 Hours</title>
        <description>The percentage of patients who experienced grade 1, 2 or 3 vomiting from time 0 to 120 hours. Nausea graded using the National Cancer Institute (NCI) CTCAE v 4.0 vomiting Grading Scale. Grade 1=Loss of appetite without alteration in eating habits, Grade 2= Oral intake decreased without significant weight loss, dehydration or malnutrition, Grade 3= Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated.</description>
        <time_frame>From time 0 to 120 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Palonosetron 0.25 mg IV on Day 1)</title>
            <description>Palonosetron 0.25 mg IV once on day 1, 30 minutes prior to chemotherapy, aprepitant 125 mg orally once on day 1, 60 minutes prior to chemotherapy, then 80 mg once daily on days 2 and 3 at the same time, and dexamethasone 12 mg orally once on day 1, 30 minutes prior to chemotherapy, then 8 mg once daily on days 2 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Ondansetron 24 mg Oral on Day 1)</title>
            <description>Ondansetron 24 mg once orally on day 1, 30 minutes prior to chemotherapy, aprepitant 125 mg orally once on day 1, 60 minutes prior to chemotherapy, then 80 mg once daily on days 2 and 3, and dexamethasone 12 mg orally once on day 1, 30 minutes prior to chemotherapy, then 8 mg once daily on days 2 through 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Experienced Grade 1, 2 or 3 Vomiting From Time 0 to 120 Hours</title>
          <description>The percentage of patients who experienced grade 1, 2 or 3 vomiting from time 0 to 120 hours. Nausea graded using the National Cancer Institute (NCI) CTCAE v 4.0 vomiting Grading Scale. Grade 1=Loss of appetite without alteration in eating habits, Grade 2= Oral intake decreased without significant weight loss, dehydration or malnutrition, Grade 3= Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Days 1 through 5 following chemotherapy</time_frame>
      <desc>Patients were given a diary on the day of treatment to record symptoms experienced on days 1 through 6. Although symptoms were documented on days 1 through 6, they were only evaluated based upon days 1 through 5. The additional day of recording was instituted to ensure the investigators captured the entire day 1 through time period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A</title>
          <description>Palonosetron 0.25 mg day 1; aprepitant 125 mg day 1, 80 mg day 2-3; dexamethasone 12 mg day 1, 8 mg day 2-4</description>
        </group>
        <group group_id="E2">
          <title>Arm B</title>
          <description>Ondansetron 24 mg day 1; aprepitant 125 mg day 1, 80 mg day 2-3; dexamethasone 12 mg day 1, 8 mg day 2-4</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rachel Layman, MD</name_or_title>
      <organization>Ohio State University Medical Center</organization>
      <phone>614-293-0066</phone>
      <email>Rachel.Layman@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

